Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company that uses its proprietary INTASYL® small interfering RNA (siRNA) gene silencing technology to enhance the effectiveness of immune cells in killing tumor cells. The company is developing therapeutics that utilize INTASYL to precisely target specific proteins that weaken the body's ability to fight cancer, without requiring specialized formulations or drug delivery systems. Phio Pharmaceuticals Corp. is focused on discovering and developing innovative cancer treatments. The company operates as a single operating segment and a single reportable segment. INTASYL technology is based on RNA interference (RNAi), a biological process that inhibits gene expression or protein production. Diseases can result from incorrect protein production, excessive amounts of a specific protein, or correct protein production at the wrong location or time. RNAi offers a novel approach to drug development because RNAi compounds can be designed to silence thousands of human genes, many of which are considered "undruggable" by traditional therapeutics. The company's development efforts are based on its patented INTASYL siRNA technology, which develops specific patented compounds. INTASYL compounds consist of a unique sequence of chemically modified nucleotides (modified siRNAs) designed to target a broad range of cell types and tissues. These compounds are designed to effectively silence genes that tumors use to evade the immune system. Unlike other siRNA technologies that require cell-targeting chemical conjugates, which limit delivery to specific cell types, INTASYL aims to overcome the primary challenge of drug delivery in RNAi-based therapeutics.